Mar 12 |
Lexicon stock slides 8% after rallying 30% in prior session
|
Mar 12 |
New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease
|
Mar 12 |
Lexicon Pharmaceuticals: Moving To Maximize The Value Of Its Core Asset
|
Mar 11 |
Lexicon Pharmaceuticals GAAP EPS of -$0.20 in-line, revenue of $0.7M misses by $1.24M
|
Mar 11 |
Lexicon stock rallies 18% amid FDA update, $250M private placement
|
Mar 11 |
Lexicon Pharmaceuticals GAAP EPS of -$0.20 beats by $0.02, revenue of $0.7M misses by $0.54M
|
Mar 11 |
Lexicon announces oversubscribed $250M private placement of equity securities
|
Mar 11 |
Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates
|
Mar 11 |
Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update
|
Mar 11 |
Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities
|